About Iovance Biotherapeutics Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance…
Eagle is a fully diversified pharmaceutical company working to advance safe and effective treatments for critical care and oncology patients, their care teams, and the overall health system. https://www.eagleus.com/about/
Immunocore, LLC is a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases.
About Us AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in…
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™…
We Are Apellis We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven…
Blue Earth Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a recognized leader in the development and commercialization of novel PET radiopharmaceuticals to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by proven experts in nuclear medicine, who have expanded…
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Rare diseases aren’t just in our name: they are at the core of all that we do. We work side-by-side with rare disease communities to raise awareness, educate, and advocate for improved diagnosis. Together, we can celebrate our successes and strengthen our impact for people living with rare diseases. Learn More: https://sylvant.com/understanding-imcd/what-is-imcd/ Learn More:…
Coherus is focused on developing and commercializing a diversified portfolio of immuno-oncology therapies. The advancement of multiple clinical stage candidates underscores our commitment to immuno-oncology treatments while the biosimilar business enables us to provide better access to therapy for patients with life-altering illnesses. About Coherus Solutions™ Coherus is committed to supporting patients with reimbursement and…
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical…
Biotheranostics, Inc. represents the oncology portfolio within the Diagnostic Solutions division of Hologic, Inc. The CLIA certified, CAP accredited laboratory provides two proprietary, highly differentiated molecular diagnostic tests for breast and metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID, respectively. Breast Cancer Index (BCI) Breast Cancer Index (BCI) is the only genomic test recognized…
Cencora, formerly AmerisourceBergen, empowers oncology physician practices and ensures their patients have access to the most innovative and cost-effective specialty care close to home. Through our ION Oncology Specialty GPO Network and Oncology Supply specialty distribution, along with our portfolio of integrated Specialty Solutions, we are a unified team of specialty practice partners, committed to…
© 2021 FLASCO | Premium Website Design by The HDG
